Neuroprotection by rAAV-mediated gene transfer of bone morphogenic protein 7

BMC Neuroscience

Markus Schwaninger²  Rolf Sprengel¹  Stefan Wölfl³  Hannah Jakobi¹  Godwin Dogbevia²  Mahbubur Rahman²  Ann-Marie Heinonen¹ 

[1] Max Planck Institute for Medical Research, Jahnstrasse 29, Heidelberg D-69120, Germany;Institute of Experimental and Clinical Pharmacology and Toxicology University of Lübeck, Lübeck, Germany;Institute of Pharmacy and Molecular Biotechnology, Department of Biology Heidelberg University, Heidelberg, Germany

关键词: Ribosomal skip;    2A peptide;    Noggin;    BMP2;    BMP7;    Apoptosis;    Stroke;   

Others  :  1092034
DOI  :  10.1186/1471-2202-15-38

 received in 2013-07-18, accepted in 2014-03-05,  发布年份 2014

【 摘 要 】

Background

Bone morphogenic proteins (BMPs) promote the survival of neurons, suggesting a therapeutic application of BMPs in the treatment of acute and chronic neurodegenerative disorders. However, the application of recombinant BMPs in vivo is limited by their short half-life. To provide a continuous supply for functionally active BMPs, we expressed BMP7, BMP2 and the BMP inhibitor Noggin under the control of rAAV vectors in vivo. For visual control of rAAV-mediated BMP (v-BMP) expression we fused the secreted morphogenic polypeptides and the fluorescent reporter protein Venus via the ‘ribosomal skip’ promoting 2A peptide-bridge.

Results

In primary cortical neurons, the rAAV-expressed morphogenic polypeptides were efficiently released from the 2A-Venus fusion precursors, were secreted, correctly processed and functionally active as shown by their effects on Smad phosphorylation in HeLa cells and in primary neurons, by the protection of v-BMP7-transduced primary cortical neurons against oxidative stress, and by the activation of BMP responsive GFP in v-BMP2 transduced reporter mice. In the stroke model of middle cerebral artery occlusion rAAV-transduced v-BMP7 reduced the infarct size in mice.

Conclusion

Polycistronic rAAV vectors encoding secreted polypeptides and 2A-linked reporter proteins are potential novel therapeutic tools for the treatment of neurological and neurodegenerative diseases. Using this technique we documented that rAAV delivery of BMP7 reduced ischemic cell death in mice.

【 授权许可】

   
2014 Heinonen et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Even J, Eskander M, Kang J: Bone morphogenetic protein in spine surgery: current and future uses. The Journal of the American Academy of Orthopaedic Surgeons 2012, 20(9):547-552.
• [2]Bond AM, Bhalala OG, Kessler JA: The dynamic role of bone morphogenetic proteins in neural stem cell fate and maturation. Developmental neurobiology 2012, 72(7):1068-1084.
• [3]Kawamata T, Ren J, Chan TC, Charette M, Finklestein SP: Intracisternal osteogenic protein-1 enhances functional recovery following focal stroke. Neuroreport 1998, 9(7):1441-1445.
• [4]Lin SZ, Hoffer BJ, Kaplan P, Wang Y: Osteogenic protein-1 protects against cerebral infarction induced by MCA ligation in adult rats. Stroke 1999, 30(1):126-133.
• [5]Bani-Yaghoub M, Tremblay RG, Ajji A, Nzau M, Gangaraju S, Chitty D, Zurakowski B, Sikorska M: Neuroregenerative strategies in the brain: emerging significance of bone morphogenetic protein 7 (BMP7). Biochemistry and cell biology = Biochimie et biologie cellulaire 2008, 86(5):361-369.
• [6]Liu Y, Belayev L, Zhao W, Busto R, Saul I, Alonso O, Ginsberg MD: The effect of bone morphogenetic protein-7 (BMP-7) on functional recovery, local cerebral glucose utilization and blood flow after transient focal cerebral ischemia in rats. Brain Res 2001, 905(1–2):81-90.
• [7]Ren J, Kaplan PL, Charette MF, Speller H, Finklestein SP: Time window of intracisternal osteogenic protein-1 in enhancing functional recovery after stroke. Neuropharmacology 2000, 39(5):860-865.
• [8]Chang C-F, Lin S-Z, Chiang Y-H, Morales M, Chou J, Lein P, Chen H-L, Hoffer BJ, Wang Y: Intravenous administration of bone morphogenetic protein-7 after ischemia improves motor function in stroke rats. Stroke 2003, 34(2):558-564.
• [9]Chou J, Harvey BK, Chang CF, Shen H, Morales M, Wang Y: Neuroregenerative effects of BMP7 after stroke in rats. J Neurol Sci 2006, 240(1–2):21-29.
• [10]Harvey BK, Mark A, Chou J, Chen GJ, Hoffer BJ, Wang Y: Neurotrophic effects of bone morphogenetic protein-7 in a rat model of Parkinson’s disease. Brain Res 2004, 1022(1–2):88-95.
• [11]de Rivero Vaccari JP, Marcillo A, Nonner D, Dietrich WD, Keane RW: Neuroprotective effects of bone morphogenetic protein 7 (BMP7) treatment after spinal cord injury. Neurosci Lett 2009, 465(3):226-229.
• [12]Gratacos E, Checa N, Perez-Navarro E, Alberch J: Brain-derived neurotrophic factor (BDNF) mediates bone morphogenetic protein-2 (BMP-2) effects on cultured striatal neurones. J Neurochem 2001, 79(4):747-755.
• [13]Reiriz J, Holm PC, Alberch J, Arenas E: BMP-2 and cAMP elevation confer locus coeruleus neurons responsiveness to multiple neurotrophic factors. J Neurobiol 2002, 50(4):291-304.
• [14]Kim JD, Kang H, Larrivee B, Lee MY, Mettlen M, Schmid SL, Roman BL, Qyang Y, Eichmann A, Jin SW: Context-dependent proangiogenic function of bone morphogenetic protein signaling is mediated by disabled homolog 2. Dev Cell 2012, 23(2):441-448.
• [15]Yanagisawa M, Nakashima K, Takeda K, Ochiai W, Takizawa T, Ueno M, Takizawa M, Shibuya H, Taga T: Inhibition of BMP2-induced, TAK1 kinase-mediated neurite outgrowth by Smad6 and Smad7. Genes Cells 2001, 6(12):1091-1099.
• [16]Nakamura Y, Ozaki T, Koseki H, Nakagawara A, Sakiyama S: Accumulation of p27 KIP1 is associated with BMP2-induced growth arrest and neuronal differentiation of human neuroblastoma-derived cell lines. Biochem Biophys Res Commun 2003, 307(1):206-213.
• [17]Shin JA, Kang JL, Lee KE, Park EM: Different temporal patterns in the expressions of bone morphogenetic proteins and noggin during astroglial scar formation after ischemic stroke. Cell Mol Neurobiol 2012, 32(4):587-597.
• [18]Samanta J, Alden T, Gobeske K, Kan L, Kessler JA: Noggin protects against ischemic brain injury in rodents. Stroke 2010, 41(2):357-362.
• [19]Dummula K, Vinukonda G, Chu P, Xing Y, Hu F, Mailk S, Csiszar A, Chua C, Mouton P, Kayton RJ, Brumberg JC, Bansal R, Ballabh P: Bone morphogenetic protein inhibition promotes neurological recovery after intraventricular hemorrhage. J Neurosci 2011, 31(34):12068-12082.
• [20]Dizon ML, Maa T, Kessler JA: The bone morphogenetic protein antagonist noggin protects white matter after perinatal hypoxia-ischemia. Neurobiol Dis 2011, 42(3):318-326.
• [21]Vukicevic S, Basic V, Rogic D, Basic N, Shih MS, Shepard A, Jin D, Dattatreyamurty B, Jones W, Dorai H, Ryan S, Griffiths D, Maliakal J, Jelic M, Pastorcic M, Stavljenic A, Sampath TK: Osteogenic protein-1 (bone morphogenetic protein-7) reduces severity of injury after ischemic acute renal failure in rat. J Clin Invest 1998, 102(1):202-214.
• [22]Chen C, Cheng Y, Chen J: Transfection of Noggin in bone marrow stromal cells (BMSCs) enhances BMSC-induced functional outcome after stroke in rats. J Neurosci Res 2011, 89(8):1194-1202.
• [23]Chang CF, Morales M, Chou J, Chen HL, Hoffer B, Wang Y: Bone morphogenetic proteins are involved in fetal kidney tissue transplantation-induced neuroprotection in stroke rats. Neuropharmacology 2002, 43(3):418-426.
• [24]Mingozzi F, High KA: Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet 2011, 12(5):341-355.
• [25]Chitty DW, Tremblay RG, Ribecco-Lutkiewicz M, Haukenfrers J, Zurakowski B, Massie B, Sikorska M, Bani-Yaghoub M: Development of BMP7-producing human cells, using a third generation lentiviral gene delivery system. Journal of neuroscience methods 2012, 205(1):17-27.
• [26]Mastakov MY, Baer K, Symes CW, Leichtlein CB, Kotin RM, During MJ: Immunological aspects of recombinant adeno-associated virus delivery to the mammalian brain. J Virol 2002, 76(16):8446-8454.
• [27]Tang W, Ehrlich I, Wolff SB, Michalski AM, Wolfl S, Hasan MT, Luthi A, Sprengel R: Faithful expression of multiple proteins via 2A-peptide self-processing: a versatile and reliable method for manipulating brain circuits. J Neurosci 2009, 29(27):8621-8629.
• [28]Douin V, Bornes S, Creancier L, Rochaix P, Favre G, Prats AC, Couderc B: Use and comparison of different internal ribosomal entry sites (IRES) in tricistronic retroviral vectors. BMC biotechnology 2004, 4:16. BioMed Central Full Text
• [29]Donnelly ML, Luke G, Mehrotra A, Li X, Hughes LE, Gani D, Ryan MD: Analysis of the aphthovirus 2A/2B polyprotein ‘cleavage’ mechanism indicates not a proteolytic reaction, but a novel translational effect: a putative ribosomal ‘skip’. The Journal of general virology 2001, 82(Pt 5):1013-1025.
• [30]de Felipe P: Skipping the co-expression problem: the new 2A “CHYSEL” technology. Genetic vaccines and therapy 2004, 2(1):13. BioMed Central Full Text
• [31]Baron U, Freundlieb S, Gossen M, Bujard H: Co-regulation of two gene activities by tetracycline via a bidirectional promoter. Nucleic Acids Res 1995, 23(17):3605-3606.
• [32]Nagai T, Ibata K, Park ES, Kubota M, Mikoshiba K, Miyawaki A: A variant of yellow fluorescent protein with fast and efficient maturation for cell-biological applications. Nat Biotechnol 2002, 20(1):87-90.
• [33]Shaner NC, Campbell RE, Steinbach PA, Giepmans BNG, Palmer AE, Tsien RY: Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein. Nat Biotechnol 2004, 22(12):1567-1572.
• [34]Marcelino J, Sciortino CM, Romero MF, Ulatowski LM, Ballock RT, Economides AN, Eimon PM, Harland RM, Warman ML: Human disease-causing NOG missense mutations: effects on noggin secretion, dimer formation, and bone morphogenetic protein binding. Proc Natl Acad Sci U S A 2001, 98(20):11353-11358.
• [35]Monteiro RM, de Sousa Lopes SM, Bialecka M, de Boer S, Zwijsen A, Mummery CL: Real time monitoring of BMP Smads transcriptional activity during mouse development. Genesis 2008, 46(7):335-346.
• [36]Walsh DW, Godson C, Brazil DP, Martin F: Extracellular BMP-antagonist regulation in development and disease: tied up in knots. Trends Cell Biol 2010, 20(5):244-256.
• [37]Pilpel N, Landeck N, Klugmann M, Seeburg PH, Schwarz MK: Rapid, reproducible transduction of select forebrain regions by targeted recombinant virus injection into the neonatal mouse brain. J Neurosci Methods 2009, 182(1):55-63.
• [38]Sun L, Guo C, Liu D, Zhao Y, Zhang Y, Song Z, Han H, Chen D, Zhao Y: Protective effects of bone morphogenetic protein 7 against amyloid-beta induced neurotoxicity in PC12 cells. Neuroscience 2011, 184:151-163.
• [39]Yabe T, Samuels I, Schwartz JP: Bone morphogenetic proteins BMP-6 and BMP-7 have differential effects on survival and neurite outgrowth of cerebellar granule cell neurons. J Neurosci Res 2002, 68(2):161-168.
• [40]Cox S, Harvey BK, Sanchez JF, Wang JY, Wang Y: Mediation of BMP7 neuroprotection by MAPK and PKC IN rat primary cortical cultures. Brain Res 2004, 1010(1–2):55-61.
• [41]Chen Y, Cao L, Luo C, Ditzel DA, Peter J, Sprengel R: RANGE: gene transfer of reversibly controlled polycistronic genes. Molecular therapy Nucleic acids 2013, 2:e85.
• [42]Shevtsova Z, Malik JMI, Michel U, Bahr M, Kugler S: Promoters and serotypes: targeting of adeno-associated virus vectors for gene transfer in the rat central nervous system in vitro and in vivo. Exp Physiol 2004, 90(1):53-59.
• [43]Smith RH, Levy JR, Kotin RM: A simplified baculovirus-AAV expression vector system coupled with one-step affinity purification yields high-titer rAAV stocks from insect cells. Mol Ther 2009, 17(11):1888-1896.
• [44]Siegel G, Obernosterer G, Fiore R, Oehmen M, Bicker S, Christensen M, Khudayberdiev S, Leuschner PF, Busch CJL, Kane C, Hübel K, Dekker F, Hedberg C, Rengarajan B, Drepper C, Waldmann H, Kauppinen S, Greenberg ME, Draguhn A, Rehmsmeier M, Martinez J, Schratt GM: A functional screen implicates microRNA-138-dependent regulation of the depalmitoylation enzyme APT1 in dendritic spine morphogenesis. Nat Cell Biol 2009, 11(6):705-716.
• [45]Inta I, Paxian S, Maegele I, Zhang W, Pizzi M, Spano P, Sarnico I, Muhammad S, Herrmann O, Inta D, Baumann B, Liou HC, Schmid RM, Schwaninger M: Bim and Noxa are candidates to mediate the deleterious effect of the NF-kB subunit RelA in cerebral ischemia. J Neurosci 2006, 26(50):12896-12903.
• [46]Cetin A, Komai S, Eliava M, Seeburg PH, Osten P: Stereotaxic gene delivery in the rodent brain. Nat Protoc 2006, 1(6):3166-3173.
• [47]Herrmann O, Baumann B, De Lorenzi R, Muhammad S, Zhang W, Kleesiek J, Malfertheiner M, Köhrmann M, Potrovita I, Maegele I, Beyer C, Burke JR, Hasan MT, Bujard H, Wirth T, Pasparakis M, Schwaninger M: IKK mediates ischemia-induced neuronal cell death. Nat Med 2005, 11:1322-1329.
• [48]Zhang W, Potrovita I, Tarabin V, Herrmann O, Beer V, Weih F, Schneider A, Schwaninger M: Neuronal activation of NF-kB contributes to cell death in cerebral ischemia. J Cereb Blood Flow Metab 2005, 25:30-40.
• [49]Swanson RA, Morton MT, Tsao-Wu G, Savalos RA, Davidson C, Sharp FR: A semiautomated method for measuring brain infarct volume. J Cereb Blood Flow Metab 1990, 10(2):290-293.